SCHEMBL10043944

SCHEMBL10043944

Cc1ccc(NC(=O)NC(=O)c2ccc(C)c(-c3cc4cnc(C)cc4n(C)c3=O)c2)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.41
LYN P07948 1/20 0.41
BTK Q06187 1/20 0.41
CNR1 P21554 1/20 0.41
NPC1 O15118 3/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPK14 Q16539 8/20 0.40
RXFP1 Q9HBX9 1/20 0.39
MAPK13 O15264 1/20 0.39
RAF1 P04049 1/20 0.39
PDGFRA P16234 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
MAPK12 P53778 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL502061 0.93 CNR1 (0.48) SRCLYNBTKCNR1NPC1
SCHEMBL10043933 0.91 RAB9A (0.46) SRCNPC1ALDH1A1LMNATSHR
SCHEMBL10043948 0.90 MAPK14 (0.42) SRCNPC1MAPTMAPK14MAPK13
SCHEMBL10043928 0.89 RAB9A (0.45) NPC1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL10043936 0.89 NPC1 (0.48) NPC1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL10043946 0.87 ALDH1A1 (0.50) NPC1ALDH1A1SMN1; SMN2MAPK14MAPK13
SCHEMBL10043857 0.86 POLB (0.45) SRCNPC1ALDH1A1MAPTSMN1; SMN2
SCHEMBL10043938 0.86 MAPK14 (0.55) ALDH1A1HPGDMAPK14MAPK13RAF1
SCHEMBL501911 0.85 SYK (0.46) SRCNPC1MAPK14MAPK13RAF1
SCHEMBL10043932 0.85 MAPK14 (0.43) SRCNPC1ALDH1A1LMNAMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SRC 3/4885LYN 60/4885BTK 63/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SRC 3/4885LYN 60/4885BTK 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.